Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months1
Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs
ZUG, Switzerland, July 17, 2025--(BUSINESS WIRE)--Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months.1
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance.3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey.
"At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission."
FLEMMING ØRNSKOV, M.D., MPHCHIEF EXECUTIVE OFFICERGALDERMA
In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss.1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.
Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1
Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment.1
Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT:1
The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 91
Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9:1
85.7% of patients said their face looked less gaunt/sunken1
88.6% said they "loved" how the treatment maintained their facial structure1
88.6% of patients said they "loved" the regenerative effects of Sculptra treatment1
88.6% felt they looked better than before the injection regimen1
91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin1
Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports.1
"The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel."
Z. PAUL LORENC, M.D.CLINICAL TRIAL INVESTIGATORNEW YORK, UNITED STATES
"These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care."
MICHAEL SOMENEK, M.D.CLINICAL TRIAL INVESTIGATORWASHINGTON DC, UNITED STATES
Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report.5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey.6
*Restylane Contour is known as Restylane® Volyme™ in countries outside of the U.S.
About the studyThis phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1
About GaldermaGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.
Mansour MR, et al. The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321
Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online
Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. https://doi.org/10.1111/jocd.70094
View source version on businesswire.com: https://www.businesswire.com/news/home/20250716698427/en/
Contacts
Christian Marcoux, M.Sc.Chief Communications Officerchristian.marcoux@galderma.com +41 76 315 26 50
Richard HarbinsonCorporate Communications Directorrichard.harbinson@galderma.com +41 76 210 60 62
Céline BuguetFranchises and R&D Communications Directorceline.buguet@galderma.com +41 76 249 90 87
Emil IvanovHead of Strategy, Investor Relations, and ESGemil.ivanov@galderma.com +41 21 642 78 12
Jessica CohenInvestor Relations and Strategy Directorjessica.cohen@galderma.com +41 21 642 76 43
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders NANTES, France, July 17, 2025, 6:30pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs, today launched the inaugural edition of its Newsletter, designed specifically for individual shareholders and investors in France and internationally. " This year, OSE Immunotherapeutics celebrates the 10th anniversary of its listing on Euronext Paris and we are delighted to introduce this new communication channel for our valued individual shareholders" said Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer of OSE Immunotherapeutics. " Beyond providing updates on Company developments, the Newsletter gives us an opportunity to shine a spotlight on our teams and offer deeper insights into topics that are typically only touched on in press releases. It's also a way for us to express our appreciation for the continued trust and support of our investor community. " Published regularly in French and English, the Newsletter will be available in the 'Investors' section of the OSE Immunotherapeutics website. To subscribe to receive our Newsletters: ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Click and follow us on LinkedIn. Follow us on Fiona Dé France Contact Media: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Contact Media:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250717_Newsletter_vfError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
an hour ago
- Gizmodo
8 Healthy ‘Three-Parent' Babies Born in UK Using Pioneering IVF Technique
So-called 'three-parent' babies are thriving in the U.K. New clinical trial research shows that several healthy children in the country have been born with the DNA of three people. Doctors at Newcastle University led the study, which involved around two dozen women with a high risk of passing down harmful mutations of their mitochondria to their children. So far, eight kids have been born using an in vitro fertilization (IVF) technique that replaces a mother's damaged mitochondrial DNA with that of a donor, all of whom appear to be disease-free. The findings seem to validate this new approach to preventing these genetic disorders. 'As parents, all we ever wanted was to give our child a healthy start in life. Mitochondrial donation IVF made that possible,' said the mother of a girl born with the method in a statement from the university. 'After years of uncertainty, this treatment gave us hope—and then it gave us our baby. We look at them now, full of life and possibility, and we're overwhelmed with gratitude. Science gave us a chance.' Mitochondria are the cell's primary source of energy, but only a tiny slice of our genetic material is responsible for creating them. This mitochondrial DNA (mtDNA) is found outside the nucleus, unlike the rest of our DNA, and the genes for making mitochondria are only inherited from our mothers. Certain mutations of mtDNA are known to cause serious diseases, and women whose eggs carry these variants can pass them down to their children. The technique pioneered by Newcastle researchers sought to get around this risk in a relatively simple way. They use standard IVF to create a fertilized egg with the mother's and father's DNA, then remove the nucleus. This nucleus is inserted into a donor egg that had its nucleus removed, which is finally transplanted into the mother's uterus for a hopefully successful pregnancy. If all goes well, the resulting child carries all the nuclear DNA of their parents and the healthy mtDNA of the donor. The researchers enrolled 22 women carrying harmful mtDNA variants to undergo the IVF procedure. These women were compared to a group of women who instead received preimplantation genetic testing (PGT), a common screening technique that can select for healthy mitochondria prior to IVF (for some women, a harmful mtDNA variant will only show up occasionally in their eggs). Eight women who underwent mitochondrial donation had live births, while another woman has an ongoing pregnancy. None of the children—four boys, four girls, and a set of identical twins—have shown signs of mitochondrial disease so far, and all are reaching their developmental goals on schedule. The success rate of the technique (36%) was also similar to PGT (41%). The results were published across two studies in the New England Journal of Medicine. The findings do point to some current limitations of mitochondrial donation. Some of the children had mitochondria carrying harmful mutations, for instance. Even in these children, however, most of their cells still carried healthy mitochondria, and their levels of mutated mitochondria are likely low enough to prevent disease from emerging. But this result will merit further monitoring of the children, and it suggests the IVF method can be improved to lessen the chance of it happening. Earlier versions of mitochondrial donation have been developed, though these were eventually banned in countries like the U.S. for being too dangerous. The UK has slowly but steadily been laying the groundwork for this newer and safer technique to be cleared for widespread use (the country officially allowed the first treatment in 2018, now seven years ago). So while there may be important questions left to answer, many women living with this genetic risk may soon have a new option available that will allow them to have children of their own.
Yahoo
an hour ago
- Yahoo
Overture Life Signs Agreement With Memorial Hospital Istanbul for World's First Commercial Automated IVF Technology
Overture's ICSI.A technology enabled first babies born from automated fertilization in 2023 Platform will now support one of the highest volume IVF clinics in the world at Memorial Hospital Istanbul, expected to assist in over 6,000 IVF cycles per year – and growing PALO ALTO, Calif., July 17, 2025--(BUSINESS WIRE)--Overture Life, the innovator modernizing IVF to optimize reproductive freedom, announced the first commercial sale of an automated in vitro fertilization (IVF) platform to Memorial Hospital Istanbul, home to one of Europe's leading fertility centers. Overture's ICSI.A platform automates a complex fertilization process known as piezo-assisted intracytoplasmic sperm injection (piezo-ICSI), which uses electric pulses to fertilize eggs more gently than manual injection methods. Overture's ICSI.A enabled the first live births resulting from an automated fertilization1, in 2023. Memorial Hospital Istanbul will use the devices to simplify thousands of IVF cycles per year, with the additional efficiency expected to grow its capacity even further. The growth of automated IVF technologies is critical for patients dealing with infertility, who often struggle to access IVF, whether due to cost, capacity or the toll that multiple IVF cycles can take, emotionally and physically. Overture is dedicated to making IVF easier to perform and less expensive, enabling every embryologist and IVF center to provide premium quality regardless of location, size, or clientele. The company is now poised for rapid commercial growth, backed by peer-reviewed science and rigorous regulatory oversight. Published data suggests piezo-ICSI leads to better quality eggs and blastocytes2, resulting in higher fertility rates. In particular, ICSI.A has demonstrated high proficiency even when operated by inexperienced personnel3 – an important factor given the years of training and practice typically needed to optimize this skillset among embryologists. "Memorial Hospitals have some of the best embryologists in the world, making us a magnet in the region for those struggling with infertility. Despite our proficiency, demand continues to rise, and we are committed to maintaining the best quality as we expand capacity," said Prof Dr Semra Kahraman of the In Vitro Fertilization (IVF) Andrology and Genetics Center at Memorial Hospital Istanbul. "Automated platforms like Overture Life's ICSI.A are game-changing technologies, and will be key for helping us scale effectively." "This exciting commercial commitment from Memorial Hospital, known worldwide for its impressive IVF clinic, is the latest milestone to cement Overture's leadership in the IVF automation space," said Hans Gangeskar, CEO of Overture Life. "This year has already seen a sizable strategic fundraise, regulatory clearance and commercialization for our DaVitri platform for fertility preservation, and CLIA licensure for our AI-powered, non-invasive metabolomic test for embryo selection, m|z. We look forward to rolling out ICSI.A in Turkey and changing the lives of more families eager to take control of their own destiny." Memorial Hospital Istanbul is expected to install Overture Life's ICSI.A robots by the end of this year. About Overture Life Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture's backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility. 1 The first babies conceived with a sperm-injecting robot have been born [Internet]. MIT Technology Review. Available from: 2 Furuhashi K, Saeki Y, Enatsu N, Iwasaki T, Ito K, Mizusawa Y, Matsumoto Y, Kokeguchi S, Shiotani M. Piezo-assisted ICSI improves fertilization and blastocyst development rates compared with conventional ICSI in women aged more than 35 years. Reprod Med Biol. 2019 Aug 24;18(4):357-361. doi: 10.1002/rmb2.12290. PMID: 31607795; PMCID: PMC6780025.3 Costa-Borges N, Munné S, Albó E, Mas S, Castelló C, Giralt G, Lu Z, Chau C, Acacio M, Mestres E, Matia Q, Marquès L, Rius M, Márquez C, Vanrell I, Pujol A, Mataró D, Seth-Smith M, Mollinedo L, Calderón G, Zhang J. First babies conceived with Automated Intracytoplasmic Sperm Injection. Reprod Biomed Online. 2023 Sep;47(3):103237. doi: 10.1016/ Epub 2023 May 25. PMID: 37400320. View source version on Contacts Media Contact overture@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
